This week, our featured physician executive is Binh Nguyen, M.D., Ph.D.
Binh Nguyen, M.D., Ph.D. is Vice President of Clinical Affairs at Endocyte. Dr. Nguyen has more than 20 years of experience in clinical drug development. He was previously Chief Medical Officer at Tigris Pharmaceuticals. Prior to this, he worked at Eli Lilly for 10 years, most recently as Executive Director, Global Oncology Platform Team, for which he was responsible for the global development of Gemzar®, Alimta®, and Enzastaurin. Dr. Nguyen's work contributed to the global approvals of Alimta® and Gemzar® in six indications: mesothelioma, first and second-line non-small cell lung cancer, as well as pancreatic, bladder, breast and ovarian cancers.
Dr. Nguyen received his Ph.D. in organic chemistry from Georgetown University and his M.D. from the University of Maryland. He completed fellowships at the National Cancer Institute and worked at the FDA's Division of Oncology as a medical reviewer.